ADMA Biologics is trading 5.25% down now at $8.66 after Berger Montague announced a September 14, 2026 investigation into potential board breaches tied to alleged channel-stuffing and declining ASCENIV demand.
- Shareholder litigation alleges distributors received rebates and extended payment terms to absorb excess inventory.
- Broader biotech weakness and rising Treasury yields are adding pressure, but the company-specific investigation appears to be the primary catalyst.